• Qiao Li, Qiuju Zhang, Yili Liu, Shan Zhao, Bo Zhang, and Bingxin Xie.
• Department of Endocrinology, Southern Branch of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
• Medicine (Baltimore). 2022 Dec 16; 101 (50): e31803e31803.

BackgroundThere is no evidence-based data to confirm the efficacy of Yiqi Yangyin Jiedu Decoction (YYJD) in postoperative thyroid cancer patients. Therefore, in order to provide new evidence-based medical evidence for clinical treatment, we used this protocol to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of YYJD in postoperative patients with thyroid cancer.MethodsThis systematic review and meta-analysis has been prospectively registered in the PROSPERO (No. CRD42022365826). Six databases, including Medicine, Embase, Cochrane, CNKI, Wan Fang, and VIP, will be searched from their inception to February 1, 2023. Clinical controlled studies investigating the efficacy and safety of YYJD in patients after thyroid cancer surgery will all be considered for inclusion. The primary outcomes are tumor recurrence rate and overall survival. The secondary outcomes include treatment-related adverse effects, length of hospital stay, and patient satisfaction. All data will be analyzed using R version 3.4.3 to calculate pooled standardized mean differences for outcomes. Data that can not be retrieved will be interpreted from graphs using digital ruler software.ResultsThe results of this paper will fill a gap in the literature regarding this project.ConclusionWe assume that the YYJD has a positive effect.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

22 keywords...

hide…